{"id":"W2935807963","doi":"10.1634/theoncologist.2018-0695","title":"Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Lung cancer; Erlotinib Hydrochloride; Epidermal growth factor receptor; Oncology; Population; ERBB3; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002135416,0.001884863,0.003183037,0.0004307603,0.0004468613,0.001367064,0.000972473,0.001283364,0.004910995],"category_scores_gemma":[0.001572864,0.0008122858,0.001740403,0.0004264196,0.001234758,0.001167265,0.0004532447,0.003054631,0.0009855818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001016124,"about_ca_system_score_gemma":0.001496183,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007589145,"about_ca_topic_score_gemma":0.001881411,"domain_scores_codex":[0.999135,0.0005056213,0.00004314406,0.000144448,0.00005545785,0.0001163574],"domain_scores_gemma":[0.9989933,0.000217369,0.000218415,0.00009323369,0.00007938354,0.0003982332],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9789321,0.007443739,0.0007921258,0.0001945127,0.0006071722,0.00003892407,0.00003091411,0.0003805541,0.002734045,0.00007796096,0.0006116029,0.008156412],"study_design_scores_gemma":[0.926645,0.07032034,0.001392697,0.000009257486,0.0002474302,0.00003246389,0.00001399991,0.0005192743,0.0003311499,0.0001078163,0.000370854,0.000009559179],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874822,0.00255462,0.0009297779,0.0007589697,0.0007557382,0.00435217,0.001184754,0.0001276976,0.001854065],"genre_scores_gemma":[0.9883956,0.001095811,0.001236232,0.0008906313,0.0005287478,0.004114683,0.001487866,0.00002249348,0.002227801],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004910995,"threshold_uncertainty_score":0.01642895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01157483162358094,"score_gpt":0.3207546105925388,"score_spread":0.3091797789689579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}